Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

1 Jan 2015

Abstract excerpt

UNLABELLED: Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found that subtype C integrase proteins have a low enzymatic cost associated with the G118R substitution, mostly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Enzyme Structure and Function
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25552724
DOI: 10.1128/jvi.03353-14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV IntegrasePMID 25552724Read ↗

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.Semantic proximity Read ↗

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistanceSemantic proximity Read ↗

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitorsSemantic proximity Read ↗

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.Semantic proximity Read ↗

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.Semantic proximity Read ↗

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.Semantic proximity Read ↗

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.Semantic proximity Read ↗

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.Semantic proximity Read ↗

Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study.Semantic proximity Read ↗

Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.